SYNDAX PHARMACEUTICALS INC (SNDX) — insider trading
Health Care · NASDAQ
SYNDAX PHARMACEUTICALS INC (SNDX) has 28 reported SEC Form 4 insider transactions in our data, including 9 open-market sales among the most recent 28 (latest 2026-07-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 32,375 | — | $0 | Form 4 |
| 2026-07-08 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Open-market sale | 32,375 | $24.24 | $784.8K | Form 4 |
| 2026-07-08 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 32,375 | $6.38 | $206.6K | Form 4 |
| 2026-06-12 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Option exercise / conversion (derivative) | 31,235 | — | $0 | Form 4 |
| 2026-06-12 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Open-market sale | 31,235 | $18.14 | $566.6K | Form 4 |
| 2026-06-12 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Option exercise / conversion | 31,235 | $13.82 | $431.7K | Form 4 |
| 2026-06-11 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Option exercise / conversion (derivative) | 22,515 | — | $0 | Form 4 |
| 2026-06-11 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Open-market sale | 34,280 | $18.00 | $617.0K | Form 4 |
| 2026-06-11 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Option exercise / conversion | 22,515 | $13.82 | $311.2K | Form 4 |
| 2026-06-01 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Open-market sale | 6,847 | $18.99 | $130.0K | Form 4 |
| 2026-06-01 | Goldan Keith A. | Officer (Chief Financial Officer) | Open-market sale | 1,177 | $18.99 | $22.4K | Form 4 |
| 2026-02-09 | Goldan Keith A. | Officer (Chief Financial Officer) | Open-market sale | 3,410 | $21.03 | $71.7K | Form 4 |
| 2026-02-09 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Open-market sale | 17,159 | $21.03 | $360.8K | Form 4 |
| 2026-02-06 | Goldan Keith A. | Officer (Chief Financial Officer) | Open-market sale | 2,082 | $20.62 | $42.9K | Form 4 |
| 2026-02-06 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Open-market sale | 7,412 | $20.62 | $152.8K | Form 4 |
| 2026-02-04 | Podlesak Dennis | Director | Grant / award / vesting | 48,000 | — | $0 | Form 4 |
| 2026-02-04 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Grant / award / vesting (derivative) | 144,700 | $20.43 | $2.96M | Form 4 |
| 2026-02-04 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Grant / award / vesting | 36,000 | — | $0 | Form 4 |
| 2026-02-04 | Botwood Nicholas A.J. | Officer (Head of R&D, CMO) | Grant / award / vesting | 24,000 | — | $0 | Form 4 |
| 2026-02-04 | Huber Martin H. Jr. | Director | Grant / award / vesting | 24,000 | — | $0 | Form 4 |
| 2026-02-04 | Jarrett Jennifer | Director | Grant / award / vesting | 24,000 | — | $0 | Form 4 |
| 2026-02-04 | Goldan Keith A. | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 118,000 | $20.43 | $2.41M | Form 4 |
| 2026-02-04 | Goldan Keith A. | Officer (Chief Financial Officer) | Grant / award / vesting | 30,750 | — | $0 | Form 4 |
| 2026-02-04 | Goldan Keith A. | Officer (Chief Financial Officer) | Grant / award / vesting | 21,500 | — | $0 | Form 4 |
| 2026-02-04 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 440,000 | $20.43 | $8.99M | Form 4 |
| 2026-02-04 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 144,600 | — | $0 | Form 4 |
| 2026-02-04 | Metzger Michael A | Director, Officer (Chief Executive Officer) | Grant / award / vesting | 73,000 | — | $0 | Form 4 |
| 2026-01-30 | Goldan Keith A. | Officer (Chief Financial Officer) | Other acquisition or disposition | 1,219 | $8.48 | $10.3K | Form 4 |
Ask the chat about SNDX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SYNDAX PHARMACEUTICALS INC (SNDX).
Last updated 2026-07-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.